TXMD — TherapeuticsMD Cashflow Statement
0.000.00%
Last trade - 00:00- $20.14m
- $13.02m
- $1.76m
- 54
- 42
- 78
- 60
Annual cashflow statement for TherapeuticsMD, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -184 | -172 | 112 | -10.3 | -2.18 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 26.3 | 24.4 | -113 | -21.3 | 0.744 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.32 | 4.59 | -4.09 | -17.4 | 1.66 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -159 | -143 | -4.08 | -48.1 | 0.732 |
| Capital Expenditures | -1.6 | -2.22 | -0.355 | 0 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0 | 224 | 0 | — |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.6 | -2.22 | 223 | 0 | — |
| Financing Cash Flow Items | -1.25 | -5.12 | -1.27 | — | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 80.7 | 130 | -235 | 3.15 | 0 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -80.3 | -15.4 | -15.8 | -45 | 0.732 |